WPD Pharmaceuticals Inc. announced that first patient enrolled in the Phase 1B/2 clinical trial of Annamycin in the treatment of soft tissue sarcoma (STS) lung metastases, has received the first dose of Annamycin. The start of clinical trial is a consequence of the project granted by Agencja Bada Medycznych (The Medical Research Agency), that was communicated by WPD in a news release dated February 9, 2021. Agencja Bada Medycznych (The Medical Research Agency) is a Polish state agency responsible for development of scientific research in the field of medical and health sciences, awarded a grant equivalent to USD 1.5 million to the Maria Sklodowska-Curie National Research Institute to fund a Phase 1B/2 clinical trial of Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.